Jill Howe
Director of Finance/CFO at LINEAGE CELL THERAPEUTICS, INC.
Net worth: 20 426 $ as of 30/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Brian Culley | M | 53 | 6 years | |
| Steffen Mueller | M | - |
Codagenix, Inc.
 Codagenix, Inc. Medical/Nursing ServicesHealth Services Codagenix, Inc. provides platform technology to construct viral vaccines against multiple targets. It focuses on SAVE platform technology that utilizes computer-based rational design of viral genomes for the design and construction of vaccines for a range of medically important human diseases. The company was founded by J. Robert Coleman, Eckard Wimmer, Charlie Petty and Steffen Mueller in 2009 and is headquartered in Farmingdale, NY. | 15 years |
| Jeffrey Alter | M | 61 | 5 years | |
| Bryan Giraudo | M | 49 | 6 years | |
| Michael Mulroy | M | 58 | 10 years | |
| Eric d'Esparbes | M | 56 | 5 years | |
| Alan Joelson | M | - |
DTx Pharma, Inc.
 DTx Pharma, Inc. Pharmaceuticals: MajorHealth Technology DTx Pharma, Inc. engages in the provision of biotechnology solutions. It focuses on the utilization of fatty acids to enable the delivery of RNA therapeutics to tissues and organ systems beyond the liver. The company was founded by Arthur T. Suckow, John Grundy, and Adam Pavlicek in August 2017 and is headquartered in San Diego, CA. | 3 years |
| Brian Kotzin | M | 74 | 5 years | |
| J. Robert Coleman | M | - |
Codagenix, Inc.
Codagenix, Inc. Medical/Nursing ServicesHealth Services Codagenix, Inc. provides platform technology to construct viral vaccines against multiple targets. It focuses on SAVE platform technology that utilizes computer-based rational design of viral genomes for the design and construction of vaccines for a range of medically important human diseases. The company was founded by J. Robert Coleman, Eckard Wimmer, Charlie Petty and Steffen Mueller in 2009 and is headquartered in Farmingdale, NY. | 15 years |
| Eckard Wimmer | M | - |
Codagenix, Inc.
Codagenix, Inc. Medical/Nursing ServicesHealth Services Codagenix, Inc. provides platform technology to construct viral vaccines against multiple targets. It focuses on SAVE platform technology that utilizes computer-based rational design of viral genomes for the design and construction of vaccines for a range of medically important human diseases. The company was founded by J. Robert Coleman, Eckard Wimmer, Charlie Petty and Steffen Mueller in 2009 and is headquartered in Farmingdale, NY. | 15 years |
| Lynne Powell | F | 57 | 5 years | |
| Adi Mohanty | M | 57 | 3 years | |
| George Samuel | M | 43 | 3 years | |
| Neal Bradsher | M | 58 | 15 years | |
| Russell Cox | M | 60 | 6 years | |
| Anula Kusum Jayasuriya | M | 67 | 3 years | |
| Thomas Daniel | M | 70 | 6 years | |
| Dipti Amin | M | 60 | 3 years | |
| Don Bailey | M | 78 | 4 years | |
| Richard Aranda | M | 64 | 6 years | |
| Clarke Neumann | M | 60 | 10 years | |
| Paul Grint | M | 66 |
Codagenix, Inc.
Codagenix, Inc. Medical/Nursing ServicesHealth Services Codagenix, Inc. provides platform technology to construct viral vaccines against multiple targets. It focuses on SAVE platform technology that utilizes computer-based rational design of viral genomes for the design and construction of vaccines for a range of medically important human diseases. The company was founded by J. Robert Coleman, Eckard Wimmer, Charlie Petty and Steffen Mueller in 2009 and is headquartered in Farmingdale, NY.
Amplyx Pharmaceuticals, Inc.
 Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 8 years |
| Deborah Andrews | F | 66 | 10 years | |
| Jeffrey Allen Ferrell | M | 49 | 10 years | |
| Angus Russell | M | 68 | 10 years | |
| Jeff Boerneke | M | - | 3 years | |
| Ariella Kelman | M | - | 1 years | |
| Lisa Runco | M | - |
Codagenix, Inc.
Codagenix, Inc. Medical/Nursing ServicesHealth Services Codagenix, Inc. provides platform technology to construct viral vaccines against multiple targets. It focuses on SAVE platform technology that utilizes computer-based rational design of viral genomes for the design and construction of vaccines for a range of medically important human diseases. The company was founded by J. Robert Coleman, Eckard Wimmer, Charlie Petty and Steffen Mueller in 2009 and is headquartered in Farmingdale, NY. | 3 years |
| Glenn Rockman | M | 43 |
Codagenix, Inc.
Codagenix, Inc. Medical/Nursing ServicesHealth Services Codagenix, Inc. provides platform technology to construct viral vaccines against multiple targets. It focuses on SAVE platform technology that utilizes computer-based rational design of viral genomes for the design and construction of vaccines for a range of medically important human diseases. The company was founded by J. Robert Coleman, Eckard Wimmer, Charlie Petty and Steffen Mueller in 2009 and is headquartered in Farmingdale, NY. | 4 years |
| Allison Luo | M | 50 | 7 years | |
| Michael Rhode | M | - | - | |
| George Lykos | M | - |
MUSC Foundation for Research Development
| - |
| Deanna Weber | F | - | 6 years | |
| Robyn Hatton | F | - | 11 years | |
| Jennifer Bahr-Davidson | M | - | 14 years | |
| Perry B. Molinoff | M | 84 |
MUSC Foundation for Research Development
| 10 years |
| Derek Kelaita | M | - | 5 years | |
| Lori Rudolph-Owen | M | - |
Codagenix, Inc.
Codagenix, Inc. Medical/Nursing ServicesHealth Services Codagenix, Inc. provides platform technology to construct viral vaccines against multiple targets. It focuses on SAVE platform technology that utilizes computer-based rational design of viral genomes for the design and construction of vaccines for a range of medically important human diseases. The company was founded by J. Robert Coleman, Eckard Wimmer, Charlie Petty and Steffen Mueller in 2009 and is headquartered in Farmingdale, NY. | 3 years |
| Paul W. Shabram | M | - | 2 years | |
| Katherine Bishop | M | 58 |
DTx Pharma, Inc.
DTx Pharma, Inc. Pharmaceuticals: MajorHealth Technology DTx Pharma, Inc. engages in the provision of biotechnology solutions. It focuses on the utilization of fatty acids to enable the delivery of RNA therapeutics to tissues and organ systems beyond the liver. The company was founded by Arthur T. Suckow, John Grundy, and Adam Pavlicek in August 2017 and is headquartered in San Diego, CA. | 2 years |
| Ioana C. Hone | F | - | - | |
| Caryn Peterson | F | 65 | 6 years | |
| Steven J. Winick | M | - |
Codagenix, Inc.
Codagenix, Inc. Medical/Nursing ServicesHealth Services Codagenix, Inc. provides platform technology to construct viral vaccines against multiple targets. It focuses on SAVE platform technology that utilizes computer-based rational design of viral genomes for the design and construction of vaccines for a range of medically important human diseases. The company was founded by J. Robert Coleman, Eckard Wimmer, Charlie Petty and Steffen Mueller in 2009 and is headquartered in Farmingdale, NY. | - |
| Dennis Dougherty | M | 76 |
MUSC Foundation for Research Development
| - |
| Sharat Singh | M | - | - | |
| Robert McQuade | M | 67 |
MUSC Foundation for Research Development
| - |
| Carl W. Ehmann | M | 81 |
MUSC Foundation for Research Development
| - |
| Lawrence Olanoff | M | 72 |
MUSC Foundation for Research Development
| - |
| Art Pappas | M | 76 |
MUSC Foundation for Research Development
| - |
| Gary Hogge | M | 56 | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Sheila Gujrathi | M | 53 | 5 years | |
| Mitchell Mutz | M | 61 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 10 years |
| Surbhi Sarna | F | 38 | 2 years | |
| Wen Kai Xiang | M | - | - | |
| Kristina Burow | F | 50 | 5 years | |
| Laura Carter | M | 57 | 4 years | |
| Otello Stampacchia | M | 55 | 1 years | |
| Josh Bilenker | M | 52 | 5 years | |
| Renée Galá | F | 52 | 6 years | |
| Hutan Hashemi | M | 45 | 3 years | |
| Alexandra Hernandez | F | - | 3 years | |
| Nicole White | F | 44 | 2 years | |
| Charlie Petty | M | - |
Codagenix, Inc.
Codagenix, Inc. Medical/Nursing ServicesHealth Services Codagenix, Inc. provides platform technology to construct viral vaccines against multiple targets. It focuses on SAVE platform technology that utilizes computer-based rational design of viral genomes for the design and construction of vaccines for a range of medically important human diseases. The company was founded by J. Robert Coleman, Eckard Wimmer, Charlie Petty and Steffen Mueller in 2009 and is headquartered in Farmingdale, NY. | 3 years |
| Luisa Salter-Cid | M | 60 | 3 years | |
| Damon Silvestry | M | 56 | 2 years | |
| Qing Qing Yi | M | 52 | - | |
| Alan Fuhrman | M | 67 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 3 years |
| Denise Bevers | F | 56 |
DTx Pharma, Inc.
DTx Pharma, Inc. Pharmaceuticals: MajorHealth Technology DTx Pharma, Inc. engages in the provision of biotechnology solutions. It focuses on the utilization of fatty acids to enable the delivery of RNA therapeutics to tissues and organ systems beyond the liver. The company was founded by Arthur T. Suckow, John Grundy, and Adam Pavlicek in August 2017 and is headquartered in San Diego, CA. | 2 years |
| Jakob Dupont | M | 58 | 2 years | |
| Robert Nelsen | M | 60 | 1 years | |
| Karen Joy Shaw | M | 68 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | - |
| Carl Johan Kördel | M | 62 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 4 years |
| Richard Lim | M | 52 | - | |
| Alfred Kingsley | M | 81 | 15 years | |
| Michael Hodges | M | - |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 75 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jill Howe
- Personal Network
